Large Volume Wearable Injectors Market size was over USD 2.62 billion in 2024 and is likely to cross USD 15.23 billion by the end of 2037, witnessing more than 14.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of large volume wearable injectors is estimated at USD 2.92 billion.
The growth of the market can be attributed to the rising cases of chronic diseases becoming the major cause of death across the globe. Large-volume wearable injectors are useful to provide drugs over a prolonged time via a subcutaneous route to cure chronic diseases such as cancer and diabetes. As per a recent study in 2020, it was estimated that around 40 million people are killed globally by chronic diseases. Further, it was estimated by the Centers for Disease Control and Prevention that 6 out of 10 adults in the United States are living with one chronic disease, whereas 4 out of 10 adults have been diagnosed with more than two chronic diseases in the year 2022.
Large-volume wearable injectors are drug delivery devices used for the single-step administration of drugs to a lengthier extent. These devices are designed to stick to the patient’s body. A large reservoir is used for storing and delivering a sufficient amount of medications via subcutaneous tissues more quickly and safely. The increasing prevalence of non-communicable diseases among the global population is anticipated to bolster the demand for large-volume wearable injectors over the forecast period. According to a recent World Health Organization (WHO) study published in 2021, non-communicable diseases (NCDs) kill approximately 41 million people worldwide each year. This is equivalent to around 71% of the total global deaths.
Growth Drivers
Burgeoning Geriatric Population – The United States stated that there were 703 million people aged 65 years and above across the whole world in 2019. Further, this number is projected to rise significantly to 1.5 billion by 2050. Furthermore, it was also estimated that more than 90% of geriatrics have at least one chronic disease while 78% of them have more than one across the globe.
Growth in the geriatric has propelled the demand for large-volume wearable injectors since these devices are beneficial for drug delivery in the most convenient way. People age 65 and above are prone to have cardiovascular disease, chronic disease, or autoimmune diseases and require constant medical care. Some people aged above 70 are unable to visit the hospital more frequently but require routine check-ups or doses of drugs. In these circumstances, large-volume wearable injectors can deliver specific amounts of drugs for an extended period without any interruption.
Increase in Deaths by Cardiovascular Diseases Around the World – As per the statistics shared by the World Health Organization (WHO) in 2021, around 17.9 million people globally died due to cardiovascular diseases in 2019. It was approximately 32% of all global deaths. Cardiovascular diseases are being more prevalent than before owing to rising air pollution and an increasing number of people adopting unhealthy lifestyles.
Rising Instances of Autoimmune Diseases – The report released by the National Institute of Environmental Health Sciences revealed that more than 24 million people are affected by autoimmune illnesses.
Rise in Healthcare Expenditure across the Globe – As per the World Bank, global health expenditure accounted for 9.83% of the total GDP in 2019. This was a significant rise from 9.37% of the total GDP in 2013.
Boom in Healthcare Sector – As per recent estimates, the revenue generated by India’s healthcare sector was approximately USD 300 billion in 2020, which is further anticipated to rise to USD 380 billion by 2022.
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
14.4% |
|
Base Year Market Size (2024) |
USD 2.62 billion |
|
Forecast Year Market Size (2037) |
USD 15.23 billion |
|
Regional Scope |
|
The global large-volume wearable injectors market is segmented and analyzed for demand and supply by product type into on-body, off-body, and handheld wearable injectors. Out of the three types of products, the on-body segment is estimated to gain the largest market share in the year 2037. The growth of the segment can be attributed to the rising adoption of technologically advanced products along with rising development in wearable AI technology. Wearable AI technology comprises real-time health monitoring sensors to provide health data and other health parameters to assist healthcare providers and patients in making quick and necessary decisions. AI in healthcare is being more prevalent owing to its accuracy and convenience. For instance, in 2021, approximately 9% of healthcare organizations were observed to be using AI models. The segment growth is also supported by rising initiatives and funding to develop medical technologies across the globe. Hence, all these factors are projected to propel the growth of the segment over the forecast period.
The global large-volume wearable injectors market is also segmented and analyzed for demand and supply by therapeutic areas into cardiovascular disorders, infectious diseases, neurological disorders, oncological disorders, and others. Amongst these segments, the oncological disorders segment is expected to garner a significant share in the year 2037. The growth of the segment can be attributed to the higher utilization of wearable injectors in collecting cancer cells from patients’ cells and spiking instances of cancer across the globe. During the treatment of cancer, several drugs need to be delivered intravenously for prolonged periods, it becomes quite convenient with the help of large-volume wearable injectors since they automatically deliver drug doses at optimal times. As of 2020, around 10 million people lost their lives owing to cancer according to the data released by World Health Organization (WHO). Therefore, such a higher prevalence of cancer is projected to drive the growth of the segment over the forecast period.
Our in-depth analysis of the global large-volume wearable injectors market includes the following segments:
|
By Product Type |
|
|
By Device Type |
|
|
By Usability |
|
|
By Therapeutic Area |
|
The North American large-volume wearable injectors market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037. The growth of the market can be attributed majorly to the rising cases of chronic disease in the region. Chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in the United States. They are also the leading drivers of the nation’s USD 4.1 trillion in annual healthcare costs. Further, the boom in the healthcare industry is another growth factor for the large volume of wearable injectors market growth. The revenue generated by the U.S. healthcare industry stood at USD 800 billion as of 2021. Additionally, the growing geriatric population in the region with severe autoimmune and chronic diseases is further anticipated to propel the market growth over the forecast period. It was projected that in the United States, every 6 people out of 10 suffer from at least 1 chronic disease.
Additionally, the global large-volume wearable injectors market is anticipated to hold the second-largest share in the Asia Pacific region over the forecast period. The growth of the market in the region can ascribe a higher prevalence of cancer in the region backed by the escalating spending capacity of the population coupled with an escalation in autoimmune diseases. For instance, in 2018, approximately 8 million new cases of cancer were diagnosed in Asia Pacific while more than 5 million death occurred owing to cancer in a similar year. Furthermore, the surge in the cases of diabetes, lung diseases, and others is further estimated to expand the market size over the forecast period.
Becton, Dickinson, and Company have collaborated with LabCorp, a leading global life sciences company. This collaboration is expected to create a framework to develop, manufacture, and commercialize flow cytometry-based companion diagnostics (CDx) with life-changing treatments for cancer and other diseases.
Insulet Corporation announces full market releases of Omnipod 5 Automated Insulin Delivery (AID) System through U.S. retail pharmacy channels for individuals aged six years and older with type 1 diabetes.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?